Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection
The failure of chronic therapy with antibiotics to clear persistent respiratory infection is the key morbidity and mortality factor for patients with chronic lung diseases, primarily due to the presence of biofilm in the lungs. It is hypothesised that carbon sources, such as mannitol, could stimulate the metabolic activity of persister cells within biofilms and restore their susceptibility to antibiotics. The aims of the current study are to: (1) establish a representative in vitro model of Pseudomonas aeruginosa biofilm lung infection, and (2) investigate the effects of nebulised mannitol on antibiotic efficacy, focusing on ciprofloxacin, in the eradication of biofilm.
Air interface biofilm was cultured onto Snapwell inserts incorporated into a modified pharmacopeia deposition apparatus, the Anderson Cascade Impactor (ACI). Three different formulations including mannitol only, ciprofloxacin only and combined ciprofloxacin and mannitol were nebulised onto the P. aeruginosa biofilm using the modified ACI. Antibacterial effectiveness was evaluated using colony-forming units counts, biofilm penetration and scanning electron microscopy.
Nebulised mannitol promotes the dispersion of bacteria from the biofilm and demonstrated a synergistic enhancement of the antibacterial efficacy of ciprofloxacin compared to delivery of antibiotic alone.
The combination of ciprofloxacin and mannitol may provide an important new strategy to improve antibiotic therapy for the treatment of chronic lung infections. Furthermore, the development of a representative lung model of bacterial biofilm could potentially be used as a platform for future new antimicrobial pre-clinical screening.
KEY WORDSbiofilm ciprofloxacin inhalation mannitol respiratory tract infection
Anderson cascade impactor
American type cell culture collection
Cation adjusted Mueller-Hinton broth
Ciprofloxacin and mannitol
Centers for disease control
Colony-forming unit count
Chronic obstructive pulmonary disease
Dulbecco’s Modified Eagle’s Medium
Extracellular polymeric substances
Fetal bovine serum
Fine particle fraction
Geometric standard deviation
Hank’s balanced salt solution
High performance liquid chromatography
Mass median aerodynamic diameter
- P. aeruginosa
Phosphate buffered saline
Primary ciliary dyskinesia
Refractive index detector
Respiratory tract infections
Scanning electron microscope
Transepithelial electrical resistance
United States Pharmacopoeia
- 1.Organization WH. WHO: The top 10 causes of death. 2014 [Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
- 2.Hassett DJ, Cuppoletti J, Trapnell B, Lymar SV, Rowe JJ, Yoon SS, et al. Anaerobic metabolism and quorum sensing by Pseudomonas Aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev. 2002;54(11):1425–43.CrossRefPubMedGoogle Scholar
- 6.Clancy J, Dupont L, Konstan M, Billings J, Fustik S, Goss C, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas Aeruginosa infection. Thorax. 2013; 68(9): 818-825. https://doi.org/10.1136/thoraxjnl-2012-202230.
- 22.Haghi M, Traini D, Young P. In Vitro Cell Integrated Impactor Deposition Methodology for the Study of Aerodynamically Relevant Size Fractions from Commercial Pressurised Metered Dose Inhalers. Pharm Res. 2014;31(7):1779-87. https://doi.org/10.1007/s11095-013-1282-2.
- 27.Administration FaD. Guidance for industry; dissolution testing of immediate release solid oral dosage forms. extended release solid oral dosage forms: development, evaluation and application of in vitro/in vivo correlations 1997.Google Scholar
- 28.Moore JW, Flanner HH. Mathematical comparison of dissolution profiles. Pharm Technol. 1996;20(6):64–74.Google Scholar
- 29.Administration FaD. Guidance for industry; bioavailability and bioequivalence studies for orally administered drug products—general considerations 2000.Google Scholar
- 40.Cotton LA, Graham RJ, Lee RJ. The role of alginate in P. aeruginosa PAO1 biofilm structural resistance to gentamicin and ciprofloxacin. J Exp Microbiol Immunol. 2009;13:58–62.Google Scholar